The use of long-acting beta2- agonists as monotherapy in children and adults

Published: January 23, 2013
Category: Bibliography > Papers
Authors: Camp PG, Carleton BC, Smith MA, Zhang T
Countries: Canada
Language: null
Types: Population Health
Settings: Hospital

J Popul Ther Clin Pharmacol 20:e1.

University of British Columbia, Vancouver, BC, Canada; St. Paul’s Hospital, Vancouver, BC, Canada

BACKGROUND: In asthma, it is recommended that long-acting β2-agonists (LABAs) not be used as monotherapy, but, be used with inhaled corticosteroids (ICS) to minimize the risk of serious adverse events.

OBJECTIVE: To test the hypothesis that if clinical recommendations were followed, LABA monotherapy would not occur in children and would only occur in COPD, where it is not contraindicated.

METHODS: We analyzed LABA and ICS dispensing for British Columbians with respiratory conditions in 2004. LABA use was classified as “LABA Monotherapy”, “LABA with Concurrent ICS”, or “Mixed” (LABA use, occasional ICS use). Using physician and hospital billing records, children 18 years were classified as having “asthma” or “other respiratory condition”. Adults were classified as having “asthma”, “COPD”, “asthma and COPD”, or “other respiratory condition”. We calculated the prevalence of LABA monotherapy, and the association between LABA mootherapy and diagnosis, age, gender, and location of residence.

RESULTS: LABA monotherapy occurred in 3.4% (n=140) of pediatric and 3.9% (n=1837) of adult LABA users and in 3.4% of children with asthma and 3.0% of adults with asthma. In children, LABA monotherapy was associated with female gender (odds ratio (OR) 1.62; 95% confidence interval (CI) 1.14, 2.82; p<0.0065) and adolescence (age 12-18 years; 2.30; CI 1.53,3.46; p0.0001). In adults, LABA monotherapy was associated with a COPD diagnosis, and being greater than 60 years old (p0.0001).

CONCLUSION: LABA monotherapy occurs in children and adults. LABA monotherapy in children, especially in girls and adolescents, could expose them to serious adverse events and requires further study.

PMID: 23392793

Medications,Age,High Risk,Diagnostic Certainty,Canada,Administration,Inhalation,Adolescent,Adrenergic beta-2 Receptor Agonists/administration & dosage,Adrenergic beta-2 Receptor Agonists/adverse effects,80 and over,Anti-Asthmatic Agents/administration & dosage,Anti-Asthmatic Agents/adverse effects,British Columbia,Child,Preschool,Databases,Factual,Delayed-Action Preparations,Drug Therapy,Combination,Gender,Glucocorticoids/administration & dosage,Glucocorticoids/therapeutic use,Middle Aged,Practice Guidelines as Topic,Pulmonary Disease,Chronic Obstructive/drug therapy,Sex Factors,Young Adult

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top